{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Head+and+Neck+Cutaneous+Squamous+Cell+Carcinoma", "query": { "condition": "Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Head+and+Neck+Cutaneous+Squamous+Cell+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T04:49:15.055Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06589804", "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Neck Squamous Cell Carcinoma of Unknown Primary", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Hypopharyngeal Squamous Cell Carcinoma", "Refractory Laryngeal Squamous Cell Carcinoma", "Refractory Oral Cavity Squamous Cell Carcinoma", "Refractory Oropharyngeal Squamous Cell Carcinoma", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2025-03-27", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 200, "location_summary": "Little Rock, Arkansas • Marysville, California • Palo Alto, California + 161 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Marysville", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06589804" }, { "nct_id": "NCT04454489", "title": "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Pembrolizumab (immunotherapy)", "type": "DRUG" }, { "name": "Quad-shot palliative radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-02-25", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04454489" }, { "nct_id": "NCT04242173", "title": "Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "Cutaneous Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Cemiplimab-Rwlc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-06-25", "completion_date": "2022-05-26", "has_results": true, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 2, "location_summary": "Tucson, Arizona • Tampa, Florida", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242173" }, { "nct_id": "NCT05063552", "title": "Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Lip and Oral Cavity Carcinoma", "Metastatic Nasal Cavity Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Squamous Cell Carcinoma", "Metastatic Pharyngeal Squamous Cell Carcinoma", "Metastatic Sinonasal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Squamous Cell Carcinoma", "Recurrent Pharyngeal Squamous Cell Carcinoma", "Recurrent Sinonasal Squamous Cell Carcinoma", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Sinonasal Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2023-03-13", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 172, "location_summary": "Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Dublin", "state": "California" }, { "city": "Emeryville", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Martinez", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05063552" }, { "nct_id": "NCT06568172", "title": "Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eyelid Squamous Cell Carcinoma", "Recurrent Eyelid Squamous Cell Carcinoma", "Recurrent Skin Acantholytic Squamous Cell Carcinoma", "Recurrent Skin Clear Cell Squamous Cell Carcinoma", "Recurrent Skin Lymphoepithelial Carcinoma", "Recurrent Skin Spindle Cell Squamous Cell Carcinoma", "Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation", "Resectable Eyelid Squamous Cell Carcinoma", "Resectable Skin Acantholytic Squamous Cell Carcinoma", "Resectable Skin Clear Cell Squamous Cell Carcinoma", "Resectable Skin Lymphoepithelial Carcinoma", "Resectable Skin Spindle Cell Squamous Cell Carcinoma", "Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation", "Skin Acantholytic Squamous Cell Carcinoma", "Skin Clear Cell Squamous Cell Carcinoma", "Skin Lymphoepithelial Carcinoma", "Skin Spindle Cell Squamous Cell Carcinoma", "Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2025-02-18", "completion_date": "2031-08-14", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 196, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06568172" }, { "nct_id": "NCT04576091", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Recurrent Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Sinonasal Cancer AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Sinonasal Cancer AJCC v8", "Unresectable Head and Neck Cutaneous Squamous Cell Carcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hypopharyngeal Squamous Cell Carcinoma", "Unresectable Laryngeal Squamous Cell Carcinoma", "Unresectable Oral Cavity Squamous Cell Carcinoma", "Unresectable Oropharyngeal Squamous Cell Carcinoma", "Unresectable Paranasal Sinus Squamous Cell Carcinoma", "Unresectable Salivary Gland Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-07-06", "completion_date": "2027-01-14", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 11, "location_summary": "Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576091" }, { "nct_id": "NCT06330064", "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2024-04-10", "completion_date": "2028-07-25", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 18, "location_summary": "Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06330064" }, { "nct_id": "NCT04592484", "title": "A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CDK-002", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Codiak BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-09-15", "completion_date": "2022-12-23", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592484" }, { "nct_id": "NCT04305795", "title": "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Head and Neck Squamous Cell Carcinoma", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Locally Advanced Cutaneous Squamous Cell Carcinoma", "Metastatic Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "200 mg Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "350 mg Cemiplimab", "type": "BIOLOGICAL" }, { "name": "ASP-1929 PIT", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "Rakuten Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2020-12-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 7, "location_summary": "Miami, Florida • Lexington, Kentucky • Rochester, Minnesota + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305795" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-02T04:49:15.055Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" } ] }